Below is a transcript of the testimonial by Dr. Dale Bredesen about his experience publishing the paper, “Alzheimer’s disease as a systems network disorder: chronic stress/dyshomeostasis, innate immunity, and genetics,” with Aging (Aging-US).
When we had the first translational results in Alzheimer’s with people actually improving, which was a culmination of 30 years in the research laboratory, we wanted to find a place that was open access and so people could access this. And certainly not just scientists, physicians, and other clinicians, neuropsychologist, etc, have access to this, but also many people at risk and many families have access to this. So open access is very important.
Rapid review with experts in the field, very important. And in an area that’s been somewhat polarized with people going toward the drug side, other people going toward more of a systems biology sort of approach, I think it’s very important to have open-minded researchers who are looking toward the future, visionary researchers. And so these were all critical features going forward, and then having something that’s PubMed searchable.
So there are many journals now that are open access, but that are not on PubMed. So having all those boxes checked, made it very, very important, and this is the reason that we have repeatedly published in Aging and Oncotarget
Click here to read the full study, published by Aging (Aging-US).
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact firstname.lastname@example.org.